Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

Clemens, Eva; van den Heuvel-Eibrink, Marry M; Mulder, Renée L; Kremer, Leontien C M; Hudson, Melissa M; Skinner, Roderick; Constine, Louis S; Bass, Johnnie K; Kuehni, Claudia E; Langer, Thorsten; van Dalen, Elvira C; Bardi, Edith; Bonne, Nicolas-Xavier; Brock, Penelope R; Brooks, Beth; Carleton, Bruce; Caron, Eric; Chang, Kay W; Johnston, Karen; Knight, Kristin; ... (2019). Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet oncology, 20(1), e29-e41. Elsevier 10.1016/S1470-2045(18)30858-1

	Text Clemens LancetOncol 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (720kB) | Request a copy
Preview	Text Clemens LancetOncol 2019_manuscript.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (934kB) | Preview
Preview	Text Clemens LancetOncol 2019_manuscript_appendix.pdf - Supplemental Material Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Interest & Impact

Downloads

895 since deposited on 17 Jan 2019
140 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item